Uncategorized

7 02, 2023

FDA clears Sana Biotechnology’s CAR T Therapy IND application for patients with B-cell malignancies
Gallery

FDA clears Sana Biotechnology’s CAR T Therapy IND application for patients with B-cell malignancies

webmaster2025-06-24T14:24:35+00:00

The goal of the hypoimmune platform is to overcome the immunologic rejection of allogeneic cells, which if true for SC291 may result in longer CAR T cell persistence and a higher rate of durable complete responses for patients with B-cell lymphomas or leukemias. The hypoimmune platform includes disruption of major...

FDA clears Sana Biotechnology’s CAR T Therapy IND application for patients with B-cell malignancieswebmaster2025-06-24T14:24:35+00:00

13 12, 2022

ASGCT Members Provide Recommendations During FDA Liaison Meeting
Gallery

ASGCT Members Provide Recommendations During FDA Liaison Meeting

webmaster2025-06-24T14:24:36+00:00

ASGCT held its fifth annual liaison meeting with FDA CBER’s Office of Tissues and Advanced Therapies (OTAT) on Nov. 14, 2022. A group of Society leaders and members gave two presentations to FDA on significant topics in the field, followed by a presentation from FDA. Dr. Keith Wonnacott, ASGCT’s Regulatory Affairs Committee Chair, chaired the meeting and moderated discussion...

ASGCT Members Provide Recommendations During FDA Liaison Meetingwebmaster2025-06-24T14:24:36+00:00

Avance Biosciences Expands Bioanalytical Testing Capabilities with New LC-MS/MS Services

Join Avance at BioProcess International – September 15-18, 2025

Avance Biosciences Launches NGS Center of Excellence in Houston

Join Avance at the BioProcessing Summit – August 18-21, 2025

Avance is growing to better support biopharmaceutical drug development and manufacturing

Ensuring Data Integrity and 21 CFR Part 11 Compliance in NGS Workflows